



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/500,696	07/01/2004	Yoon-Won Kim	7037-69151-01	3101

24197 7590 12/13/2007  
KLARQUIST SPARKMAN, LLP  
121 SW SALMON STREET  
SUITE 1600  
PORTLAND, OR 97204

EXAMINER
----------

BLUMEL, BENJAMIN P

ART UNIT	PAPER NUMBER
----------	--------------

1648

MAIL DATE	DELIVERY MODE
-----------	---------------

12/13/2007

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

# Office Action Summary

Application No.

10/500,696

Applicant(s)

KIM ET AL.

Examiner

Benjamin P. Blumel

Art Unit

1648

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 05 October 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-12 is/are pending in the application.
- 4a) Of the above claim(s) 4-9, 11 and 12 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1, 3 and 10 is/are rejected.
- 7) ☒ Claim(s) 2 is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on July 1, 2004 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

## Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some \* c) ☐ None of:
- 1) ☒ Certified copies of the priority documents have been received.
  - 2) ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - 3) ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

## Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date <u>October 5, 2007</u> . | 6) <input type="checkbox"/> Other: _____  |

### **DETAILED ACTION**

Applicants are informed that the rejections of the previous Office action not stated below have been withdrawn from consideration in view of the Applicant's arguments and/or amendments.

#### ***Election/Restrictions***

This application contains claims 4-9, 11 and 12 drawn to an invention nonelected with traverse in the reply filed on February 13, 2007. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

#### ***Information Disclosure Statement***

The information disclosure statement (IDS) submitted on October 5, 2007 was filed after the mailing date of the Non-Final Office action on April 5, 2007. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.

#### ***Response to Arguments***

Applicant's arguments filed October 5, 2007 have been fully considered but they are not persuasive. See responses below with regard to the maintained enablement rejection over only claim 10.

#### ***Claim Rejections - 35 USC § 112***

**(New Rejection Necessitated by Amendments)** Claims 1, 3 and 10 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a VSF produced by the hydridoma 4D1B (accession number KCLRF-BP-00052) with a stability at 56°C

for about 40 minutes, does not reasonably provide enablement for any viral suppressing factor having stability at 56°C for about 40 minutes. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims.

Factors to be considered in determining whether a disclosure would require undue experimentation have been summarized in Ex parte Forman, 230 USPQ 546 (BPAI 1986) and reiterated by the Court of Appeals in In re Wands, 8 USPQ2d 1400 at 1404 (CAFC 1988). The factors to be considered in determining whether undue experimentation is required include: (1) the quantity of experimentation necessary, (2) the amount or direction presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims.

The Board also stated that although the level of skill in molecular biology is high, the results of experiments in genetic engineering are unpredictable. While all of these factors are considered, a sufficient amount for a prima facie case are discussed below.

The claimed invention is drawn to an isolated VSF with various characteristics as claimed in parts (a)-(g) of claim 1. However, based on the unpredictable nature of any viral suppressant factors similar to that of the claimed VSF, particularly with regard to heat stability, the specification does not enable any person skilled in the art to make the invention commensurate in scope with these claims. The state of the art as taught by Kim et al. (see previous Office action) shows that not all isolated viral inhibitory substances (VIS) released by EMC-DV stimulated hybridomas are stable at the claimed temperature over the same amount of

time. Therefore, given that Kim et al. used a similar method of obtaining their VIS as in the instant invention, and the presence of only one such viral suppressing factor produced by the hybridoma 4D1B as described in the disclosure, undue experimentation exists in determining what VSFs would have stability at 56°C for about 40 minutes.

**(Prior Rejection Maintained)** Claim 10 is rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for treatment of EMC-DV induced diabetes development in mice, does not reasonably provide enablement for preventing and/or treating all viral infections claimed. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

Applicants argue that since the elected invention is not directed to a method of treating viral infections and given that the specification provides a significant number of examples demonstrating anti-viral activity of VSF, their invention is in fact enabled.

In response, the examiner acknowledges that a method is not being claimed, however in view of the MPEP § 2106 (II) (C), which states “The subject matter of a properly construed claim is defined by the terms that limit its scope. It is this subject matter that must be examined. As a general matter, the grammar and intended meaning of terms used in a claim will dictate whether the language limits the claim scope”. Furthermore, as also discussed in the above cited MPEP section, we as patent application examiners are required to give the claimed invention its broadest reasonable interpretation in view of the specification, but without further limiting the claimed invention via particulars of the specification. With regard to the arguments pertaining to

*in vivo* experiments not being necessary given the full scope of the claims and the significant number of experiments presented in the disclosure, the applicants have not shown any aspect of preventing viral infections. Moreover, since the broadest reasonable interpretation of the claimed invention provides for a pharmaceutical composition that can be administered *in vivo*, and since the invention recites preventing viral infections, working examples that support this claim are necessary given the nature of the invention, and unpredictable nature of the art as discussed in the previous Office action. Therefore, the claimed invention is drawn to a pharmaceutical composition of a VSF protein that is capable of **preventing** or treating viral infection, as stated in the previous Office action. Given the guidance of the MPEP and the presently claimed invention in addition to the discussion of the previous Office action, the specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

#### ***Claim Objections***

Claim 2 is objected to because of the following informalities: claim 2 recites, "...polypeptide has a DNA sequence..." in lines 3 and 5. It is suggested that applicants amend claim to recite "...polypeptide is encoded by a DNA sequence...". Appropriate correction is required.

Claim 2 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

***Summary***

No claims are allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a).

Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

***Conclusion***


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Benjamin P. Blumel whose telephone number is 571-272-4960. The examiner can normally be reached on M-F, 8-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on 571-272-1600. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.


Application/Control Number:  
10/500,696  
Art Unit: 1648

Page 7

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



/Benjamin P Blumel/  
Examiner  
Art Unit 1648



**BRUCE R. CAMPELL, PH.D**  
**SUPERVISORY PATENT EXAMINER**  
**TECHNOLOGY CENTER 1600**